Long-Acting Opioid REMS Tally: FDA Lists 12 Brand, 23 Generic

Nineteen companies will implement individual Risk Evaluation and Mitigation Strategies for long-acting/extended-release opioid products that are subject to the class-wide REMS unveiled by FDA July 9.